Navid Farr1, Yak-Nam Wang2, Samantha D'Andrea3, Frank Starr2, Ari Partanen4, Kayla M Gravelle3, Jeannine S McCune5, Linda J Risler5, Stella G Whang3, Amy Chang6, Sunil R Hingorani3,6, Donghoon Lee7, Joo Ha Hwang3. 1. a Department of Bioengineering , University of Washington , Seattle , WA , USA. 2. b Applied Physics Laboratory , University of Washington , Seattle , WA , USA. 3. c Department of Medicine , University of Washington , Seattle , WA , USA. 4. d Philips, Clinical Science MR Therapy , Andover , MA , USA. 5. e Pharmacokinetics Laboratory , University of Washington , Seattle , WA , USA. 6. f Fred Hutchinson Cancer Research Center , Seattle , WA , USA. 7. g Department of Radiology , University of Washington , Seattle , WA , USA.
Abstract
PURPOSE: The lack of effective treatment options for pancreatic cancer has led to a 5-year survival rate of just 8%. Here, we evaluate the ability to enhance targeted drug delivery using mild hyperthermia in combination with the systemic administration of a low-temperature sensitive liposomal formulation of doxorubicin (LTSL-Dox) using a relevant model for pancreas cancer. MATERIALS AND METHODS: Experiments were performed in a genetically engineered mouse model of pancreatic cancer (KPC mice: LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre). LTSL-Dox or free doxorubicin (Dox) was administered via a tail vein catheter. A clinical magnetic resonance-guided high intensity focussed ultrasound (MR-HIFU) system was used to plan treatment, apply the HIFU-induce hyperthermia and monitor therapy. Post-therapy, total Dox concentration in tumour tissue was determined by HPLC and confirmed with fluorescence microscopy. RESULTS: Localized hyperthermia was successfully applied and monitored with a clinical MR-HIFU system. The mild hyperthermia heating algorithm administered by the MR-HIFU system resulted in homogenous heating within the region of interest. MR-HIFU, in combination with LTSL-Dox, resulted in a 23-fold increase in the localised drug concentration and nuclear uptake of doxorubicin within the tumour tissue of KPC mice compared to LTSL-Dox alone. Hyperthermia, in combination with free Dox, resulted in a 2-fold increase compared to Dox alone. CONCLUSION: This study demonstrates that HIFU-induced hyperthermia in combination with LTSL-Dox can be a non-invasive and effective method in enhancing the localised delivery and penetration of doxorubicin into pancreatic tumours.
PURPOSE: The lack of effective treatment options for pancreatic cancer has led to a 5-year survival rate of just 8%. Here, we evaluate the ability to enhance targeted drug delivery using mild hyperthermia in combination with the systemic administration of a low-temperature sensitive liposomal formulation of doxorubicin (LTSL-Dox) using a relevant model for pancreas cancer. MATERIALS AND METHODS: Experiments were performed in a genetically engineered mouse model of pancreatic cancer (KPC mice: LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre). LTSL-Dox or free doxorubicin (Dox) was administered via a tail vein catheter. A clinical magnetic resonance-guided high intensity focussed ultrasound (MR-HIFU) system was used to plan treatment, apply the HIFU-induce hyperthermia and monitor therapy. Post-therapy, total Dox concentration in tumour tissue was determined by HPLC and confirmed with fluorescence microscopy. RESULTS: Localized hyperthermia was successfully applied and monitored with a clinical MR-HIFU system. The mild hyperthermia heating algorithm administered by the MR-HIFU system resulted in homogenous heating within the region of interest. MR-HIFU, in combination with LTSL-Dox, resulted in a 23-fold increase in the localised drug concentration and nuclear uptake of doxorubicin within the tumour tissue of KPC mice compared to LTSL-Dox alone. Hyperthermia, in combination with free Dox, resulted in a 2-fold increase compared to Dox alone. CONCLUSION: This study demonstrates that HIFU-induced hyperthermia in combination with LTSL-Dox can be a non-invasive and effective method in enhancing the localised delivery and penetration of doxorubicin into pancreatic tumours.
Entities:
Keywords:
Focused ultrasound; KPC mouse model; hyperthermia; magnetic resonance imaging; pancreatic cancer
Authors: Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani Journal: Cancer Cell Date: 2012-03-20 Impact factor: 31.743
Authors: Nadia K Malik; Kilian Salerno May; Rameela Chandrasekhar; Wen Wee; Leayn Flaherty; Renuka Iyer; John Gibbs; Boris Kuvshinoff; Gregory Wilding; Graham Warren; Gary Y Yang Journal: J Gastrointest Oncol Date: 2012-12
Authors: Tong Li; Yak-Nam Wang; Tatiana D Khokhlova; Samantha D'Andrea; Frank Starr; Hong Chen; Jeannine S McCune; Linda J Risler; Afshin Mashadi-Hossein; Sunil R Hingorani; Amy Chang; Joo Ha Hwang Journal: Cancer Res Date: 2015-07-27 Impact factor: 12.701
Authors: Monica M Mita; Ronald B Natale; Edward M Wolin; Brenda Laabs; Hillary Dinh; Scott Wieland; Daniel J Levitt; Alain C Mita Journal: Invest New Drugs Date: 2014-11-12 Impact factor: 3.850
Authors: Dickson K Kirui; Juahua Mai; Anna-Lisa Palange; Guoting Qin; Anne L van de Ven; Xuewu Liu; Haifa Shen; Mauro Ferrari Journal: PLoS One Date: 2014-02-18 Impact factor: 3.240
Authors: Lifei Zhu; Michael B Altman; Andrei Laszlo; William Straube; Imran Zoberi; Dennis E Hallahan; Hong Chen Journal: Ultrasound Med Biol Date: 2019-02-14 Impact factor: 2.998
Authors: H Petra Kok; Erik N K Cressman; Wim Ceelen; Christopher L Brace; Robert Ivkov; Holger Grüll; Gail Ter Haar; Peter Wust; Johannes Crezee Journal: Int J Hyperthermia Date: 2020 Impact factor: 3.914
Authors: Maxime Lafond; Thomas Lambin; Robert Andrew Drainville; Aurélien Dupré; Mathieu Pioche; David Melodelima; Cyril Lafon Journal: Cancers (Basel) Date: 2022-05-24 Impact factor: 6.575
Authors: Nahid S Awad; Vinod Paul; Nour M AlSawaftah; Gail Ter Haar; Theresa M Allen; William G Pitt; Ghaleb A Husseini Journal: ACS Pharmacol Transl Sci Date: 2021-03-03